Molecular Insight Pharmaceuticals, Inc. Begins Phase 2 Zemiva™ Trial for Compilation of Normal Cardiac Images

Reference Database Part of Clinical Program to Develop Zemiva™ for Imaging Cardiac Ischemia

Cambridge, MA, March 27, 2006 – Molecular Insight Pharmaceuticals, Inc. today announced the start of a Phase 2 clinical trial to develop a reference database of normal Zemiva™ images of the heart using SPECT imaging. The normative trial is part of Molecular Insight's ongoing clinical program to develop Zemiva™ (iodofiltic acid I 123) for the diagnosis of cardiac ischemia in chest pain patients in the emergency department setting. Currently, an estimated six to eight million chest pain patients in the United States require determination of whether their chest pain is caused by insufficient blood flow to the heart each year. Tools such as a Normals reference database are commonly used in the field of nuclear cardiology to enable an interpreting physician to compare a patient's cardiac image against that of a population-based "normal" image.

The normative trial is designed to include approximately 120 patients at 12 centers in North America. It follows earlier Phase 2 safety and efficacy studies of Zemiva™ and is expected to be completed in approximately six months. Molecular Insight intends to use the Normals reference database in its registration trials for Zemiva™ and in commercialization of the product, if approved by the FDA.

About Molecular Insight Pharmaceuticals, Inc.
Molecular Insight Pharmaceuticals is a biopharmaceutical company focused on the research, development and commercialization of innovative molecular imaging pharmaceuticals and targeted radiotherapeutics. The company's product candidates target markets with significant unmet needs in cardiology, oncology, and neurology. Molecular Insight's lead product candidate, Zemiva™ (iodofiltic acid I 123) is a radiolabeled fatty acid analog that is in development as a molecular imaging pharmaceutical for the diagnosis of insufficient blood flow to the heart, or cardiac ischemia. The company's second lead product candidate, Azedra™ (Ultratrace™ iobenguane I 131), is in development for the diagnosis and treatment of neuroendocrine tumors. Molecular Insight Pharmaceuticals is based in Cambridge, Massachusetts. The company’s website is: www.molecularinsight.com.

Contact:
Priscilla Harlan
Vice President, Corporate Communications
Molecular Insight Pharmaceuticals, Inc.
(617) 492-5554